- Home
- PRME vs ATXS Comparison
PRME vs ATXS Comparison
Compare PRME & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- ATXS
- Stock Information
- Founded
- PRME 2019
- ATXS 2008
- Country
- PRME United States
- ATXS United States
- Employees
- PRME N/A
- ATXS N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- ATXS Health Care
- Exchange
- PRME Nasdaq
- ATXS Nasdaq
- Market Cap
- PRME 588.2M
- ATXS 573.8M
- IPO Year
- PRME 2022
- ATXS 2015
- Fundamental
- Price
- PRME $3.55
- ATXS $11.12
- Analyst Decision
- PRME Strong Buy
- ATXS Strong Buy
- Analyst Count
- PRME 9
- ATXS 5
- Target Price
- PRME $14.75
- ATXS $26.00
- AVG Volume (30 Days)
- PRME 524.5K
- ATXS 310.9K
- Earning Date
- PRME 11-01-2024
- ATXS 08-12-2024
- Dividend Yield
- PRME N/A
- ATXS N/A
- EPS Growth
- PRME N/A
- ATXS N/A
- EPS
- PRME N/A
- ATXS N/A
- Revenue
- PRME $591,000.00
- ATXS N/A
- Revenue This Year
- PRME N/A
- ATXS N/A
- Revenue Next Year
- PRME N/A
- ATXS N/A
- P/E Ratio
- PRME N/A
- ATXS N/A
- Revenue Growth
- PRME N/A
- ATXS N/A
- 52 Week Low
- PRME $3.47
- ATXS $4.26
- 52 Week High
- PRME $13.27
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- PRME 31.37
- ATXS 47.07
- Support Level
- PRME $4.17
- ATXS $11.15
- Resistance Level
- PRME $4.40
- ATXS $12.57
- Average True Range (ATR)
- PRME 0.30
- ATXS 0.60
- MACD
- PRME -0.03
- ATXS -0.09
- Stochastic Oscillator
- PRME 6.67
- ATXS 20.94
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.